Biocon Biologics’ $800 Million High Yield Bond Issuance

Latham & Watkins has advised the lead managers on the offering. Linklaters advised Biocon Biologics.Biocon Biologics Plc, a wholly owned subsidiary of Biocon Biologics Limited (BBL), completed…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Marco Zingaro

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here